D. Boral Capital Facilitates Apimeds Pharmaceuticals' $13.5 Million IPO

Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) successfully closed its initial public offering on May 12, 2025. The clinical stage biopharmaceutical company, developing the bee venom-based Apitox, raised $13.5 million by offering 3,375,000 shares at $4.00 per share. The shares debuted on the NYSE American under the symbol APUS on May 9, 2025.

D. Boral Capital LLC acted as the sole bookrunner for the offering. The proceeds aim to fund a Phase III clinical trial for knee osteoarthritis, initiate a multiple sclerosis study, and support general working capital needs. Legal representation for D. Boral was provided by Blank Rome LLP, while Apimeds was supported by Nelson Mullins Riley & Scarborough LLP.

The offering was made effective following regulatory approval by the SEC, with the final prospectus available through D. Boral Capital. This announcement is not a solicitation to buy securities.